How Sapu Indexed 28 Million PubMed Abstracts to Accelerate Cancer Research with Qdrant
DGX agentSapu is an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers. From its San Diego facility, the team is pioneering a nanomedicine pipeline that takes existing FDA-ap